The potential interest of the modulation of the adenosinergic system in CAD was first considered and investigated in the 2000s, and the development of potent and selective A2AR agonists has been a subject of medicinal chemistry research for the ensuing three decades [30,31,32,33]. Here, ADORA2A is linked to coronary artery disorder.